CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorImatinibHeinrich et al., 2006
BDNMT3AR882PredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaIdarubicinLaRochelle et al., 2011
BJAK2V617FPredictiveSupportsSensitivity/ResponsePolycythemia VeraPeginterferon Alfa-2bKiladjian et al., 2006
BDNMT3AR882PrognosticDoes Not SupportPoor OutcomeAcute Myeloid LeukemiaLaRochelle et al., 2011
BDNMT3AR882PrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaLey et al., 2010
BKITD816VPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaCairoli et al., 2006
BBRAFV600DiagnosticSupportsPositiveMelanomaLee et al., 2011
DPDGFRAD842IPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorCrenolanibHeinrich et al., 2012
DPDGFRAD842VPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorCrenolanibHeinrich et al., 2012
DPDGFRAD842YPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorCrenolanibHeinrich et al., 2012
DPDGFRAD842_I843delinsVMPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorCrenolanibHeinrich et al., 2012
BDNMT3AR882PrognosticDoes Not SupportAcute Myeloid LeukemiaRibeiro et al., 2012
BFLT3ITDPrognosticDoes Not SupportAcute Myeloid LeukemiaRibeiro et al., 2012
BDNMT3AR882PrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaMarcucci et al., 2012
BDNMT3AR882PrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaRibeiro et al., 2012
BDNMT3AR882PrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaMarcucci et al., 2012
EBRAFV600E AND BRAF AmplificationPredictiveSupportsResistanceColorectal CancerSelumetinibCorcoran et al., 2010
BNPM1EXON 11 MUTATIONDiagnosticSupportsNegativeAcute Myeloid LeukemiaSchnittger et al., 2005
BNPM1EXON 11 MUTATIONDiagnosticSupportsPositiveAcute Myeloid LeukemiaSchnittger et al., 2005
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGale et al., 2008
DKRASG12VPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
DALKF1174LPredictiveSupportsSensitivity/ResponseNeuroblastomaALK Inhibitor TAE684George et al., 2008
DKRASG13DPredictiveSupportsSensitivity/ResponseColorectal CancerCetuximabDe Roock et al., 2010
BDNMT3AR882PrognosticDoes Not SupportAcute Myeloid LeukemiaMarcucci et al., 2012
BFLT3ITDPrognosticDoes Not SupportAcute Myeloid LeukemiaSchnittger et al., 2011
BWT1Exon 7 MutationPrognosticDoes Not SupportAcute Myeloid LeukemiaGaidzik et al., 2009
BWT1Exon 9 MutationPrognosticDoes Not SupportAcute Myeloid LeukemiaGaidzik et al., 2009
BCEBPAMutationPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaSchlenk et al., 2008
BMGMTPromoter MethylationPrognosticSupportsBetter OutcomeGlioblastomaEsteller et al., 2000
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaGale et al., 2008
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaLinch et al., 2014
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaBecker et al., 2010
BDNMT3AR882PrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaMarcucci et al., 2012
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaSchnittger et al., 2011
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaSchnittger et al., 2011
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaSchnittger et al., 2011
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaThiede et al., 2006
BBRCA1Loss-of-functionPredictiveSupportsSensitivity/ResponseOvarian CancerOlaparibGoff, 2013
BBRCA2Loss-of-functionPredictiveSupportsSensitivity/ResponseOvarian CancerOlaparibGoff, 2013
ABCR::ABL1FusionDiagnosticSupportsPositiveChronic Myeloid LeukemiaAn et al., 2010
BCCND1OverexpressionDiagnosticSupportsPositiveBreast CancerArnold et al., 2005
DBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibYamamoto et al., 2004
BBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibAn et al., 2010
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibYamamoto et al., 2004
CEML4::ALKFusion AND ALK C1156YPredictiveSupportsResistanceLung AdenocarcinomaCrizotinibChoi et al., 2010
CEML4::ALKFusion AND ALK L1196MPredictiveSupportsResistanceLung AdenocarcinomaCrizotinibChoi et al., 2010
BEGFRT790MPredictiveSupportsResistanceLung Non-small Cell CarcinomaDacomitinibSequist et al., 2011
CFLT3ITD AND FLT3 D835YPredictiveSupportsResistanceAcute Myeloid LeukemiaSorafenibMan et al., 2012
BFLT3TKD MUTATIONPredictiveSupportsResistanceAcute Myeloid LeukemiaSorafenibZhang et al., 2008
ABCR::ABL1FusionPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaDasatinib,NilotinibAn et al., 2010
Page 5 of 96
PreviousNext